Phosphodiesterase Type III Inhibitors

Cilostazol is a phosphodiesterase type III inhibitor that inhibits degradation of cAMP, which results in decreased thromboxane A2 levels. Thromboxane A2 promotes platelet adhesion.  Cilostazol is used to treat claudication by reducing platelet "stickiness."  Bleeding and increased mortality in heart failure have been seen.

Class Drugs

• Cilostazol

Class Mechanism of Action

Inhibits phosphodiesterase type III

• Inhibits degradation of cAMP, which results in decreased thromboxane A2 synthesis

• Decreased thromboxane ultimately lowers platelet adhesion

Increased cAMP also results in vasodilation

Class Applications

Intermittent claudication

• Reduced platelet "stickiness"

• Vasodilatory properties

• Also decreases plasma triglycerides and increases HDL cholesterol, improving lipid profile of blood

Class Adverse Effects

• Headache

• GI Upset

• Bleeding

• Increased mortality in heart failure

Drug Table

Drug Name	Application	Comments	Image
Cilostazol			"Silo" "Stars"